Table 1. Baseline demography of vitamin D treated patients and untreated controls.
The figures show total number and percentage or mean ± SD.
| Parameter | Vitamin D (n = 39) | Controls (n = 39) | p-value |
|---|---|---|---|
| Sex | |||
| Male (n) | 18 (46%) | 18 (46%) | |
| Female (n) | 21 (54%) | 21 (54%) | 1 |
| Age (SD) | 61,9 ± 13 | 62,4± 13 | 0.65 |
| Type of cancer (n) | |||
| CNS | 1 | 1 | |
| Breast | 6 | 6 | |
| Colorectal | 11 | 11 | |
| Lung | 5 | 5 | |
| Gynecological | 3 | 3 | |
| Pancreas | 4 | 4 | |
| Cholangiocarcinoma | 2 | 2 | |
| Head-Neck | 2 | 2 | |
| Prostate | 5 | 5 | |
| Number of days in the study (SD) | 76 ± 21 | 76 ± 21 | 1 |
| Survival > 90 days (n) | 26 | 26 | 1 |
| Vitamin D (nmol/L) | 33 ± 26 | 38 ± 18 | 0.34 |
| CRP (mg/L) | 47 ± 76 | 67 ± 75 | 0.01* |
| Albumin (g/L) | 28 ± 6 | 27 ± 7 | 0.15 |
| ESAS QoL (points) | 5,49 ± 2,0 | 4,05 ± 2,4 | 0.02* |
| Infections (days of antibiotics) | 16% ± 19% | 15% ± 27% | 0.83 |
| Pain (μg fentanyl/h) | 31 ± 48 | 43 ± 5 | 0.20 |
| Chemotherapy (n) | 22 | 19 | 0.51 |
There was no statistically significant difference between treated and untreated patients except for CRP and ESAS QoL-score:
*p<0.05.